5R01AG061898-03 |
2021 |
$1193602 |
First-in-human SAD & MAD trials for MW151, a novel Alzheimer's disease drug candidate that attenuates proinflammatory cytokine dysregulation |
3R01AG061898-03S1 |
2021 |
$336600 |
First-in-human SAD & MAD trials for MW151, a novel Alzheimer's disease drug candidate that attenuates proinflammatory cytokine dysregulation |
5R01AG061898-02 |
2020 |
$1505935 |
First-in-human SAD & MAD trials for MW151; a novel Alzheimer's disease drug candidate that attenuates proinflammatory cytokine dysregulation |
1R01AG061898-01 |
2019 |
$1403277 |
First-in-human SAD & MAD trials for MW151; a novel Alzheimer's disease drug candidate that attenuates proinflammatory cytokine dysregulation |